JP2023552792A - 抗ｈｅｒ２免疫複合体、及びその使用 - Google Patents

抗ｈｅｒ２免疫複合体、及びその使用 Download PDF

Info

Publication number
JP2023552792A
JP2023552792A JP2023534650A JP2023534650A JP2023552792A JP 2023552792 A JP2023552792 A JP 2023552792A JP 2023534650 A JP2023534650 A JP 2023534650A JP 2023534650 A JP2023534650 A JP 2023534650A JP 2023552792 A JP2023552792 A JP 2023552792A
Authority
JP
Japan
Prior art keywords
ethoxy
alkyldiyl
immunoconjugate
cancer
hxbzl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552792A5 (https=
Inventor
シェリー エリン アッカーマン，
マイケル エヌ． アロンソ，
ロマス クディルカ，
アーサー リー，
ブライアン サフィナ，
マシュー チョウ，
Original Assignee
ボルト バイオセラピューティクス、インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボルト バイオセラピューティクス、インコーポレーテッド filed Critical ボルト バイオセラピューティクス、インコーポレーテッド
Publication of JP2023552792A publication Critical patent/JP2023552792A/ja
Publication of JP2023552792A5 publication Critical patent/JP2023552792A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023534650A 2020-12-11 2021-12-10 抗ｈｅｒ２免疫複合体、及びその使用 Pending JP2023552792A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063124367P 2020-12-11 2020-12-11
US63/124,367 2020-12-11
PCT/US2021/062816 WO2022125904A1 (en) 2020-12-11 2021-12-10 Anti-her2 immunoconjugates, and uses thereof

Publications (2)

Publication Number Publication Date
JP2023552792A true JP2023552792A (ja) 2023-12-19
JP2023552792A5 JP2023552792A5 (https=) 2024-12-10

Family

ID=79686820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534650A Pending JP2023552792A (ja) 2020-12-11 2021-12-10 抗ｈｅｒ２免疫複合体、及びその使用

Country Status (6)

Country Link
US (1) US20240091370A1 (https=)
EP (1) EP4259212A1 (https=)
JP (1) JP2023552792A (https=)
CN (1) CN116744978A (https=)
CA (1) CA3200056A1 (https=)
WO (1) WO2022125904A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023553421A (ja) * 2020-12-11 2023-12-21 ボルト バイオセラピューティクス、インコーポレーテッド がんの治療において有用な１つ以上の８－ｈｅｔ－２－にコンジュゲーションによって連結された抗ｃｅａ抗体を含む免疫複合体、及びその使用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024539993A (ja) * 2021-10-29 2024-10-31 ボルト バイオセラピューティクス、インコーポレーテッド システイン変異抗体を含むｔｌｒアゴニスト免疫複合体、及びその使用
WO2024173384A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023553421A (ja) * 2020-12-11 2023-12-21 ボルト バイオセラピューティクス、インコーポレーテッド がんの治療において有用な１つ以上の８－ｈｅｔ－２－にコンジュゲーションによって連結された抗ｃｅａ抗体を含む免疫複合体、及びその使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
NZ507557A (en) 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP2003531149A (ja) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
WO2006073921A2 (en) 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
CN107344931B (zh) * 2016-05-06 2020-09-15 上海迪诺医药科技有限公司 苯并氮杂卓衍生物、其制备方法、药物组合物及应用
MX2021002764A (es) * 2018-09-12 2021-05-12 Silverback Therapeutics Inc Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores.
JP7558205B2 (ja) * 2019-06-13 2024-09-30 ボルト バイオセラピューティクス、インコーポレーテッド 高分子支持アミノベンズアピン化合物
US20200390899A1 (en) * 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
US20230293716A1 (en) * 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
JP2024539993A (ja) * 2021-10-29 2024-10-31 ボルト バイオセラピューティクス、インコーポレーテッド システイン変異抗体を含むｔｌｒアゴニスト免疫複合体、及びその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023553421A (ja) * 2020-12-11 2023-12-21 ボルト バイオセラピューティクス、インコーポレーテッド がんの治療において有用な１つ以上の８－ｈｅｔ－２－にコンジュゲーションによって連結された抗ｃｅａ抗体を含む免疫複合体、及びその使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023553421A (ja) * 2020-12-11 2023-12-21 ボルト バイオセラピューティクス、インコーポレーテッド がんの治療において有用な１つ以上の８－ｈｅｔ－２－にコンジュゲーションによって連結された抗ｃｅａ抗体を含む免疫複合体、及びその使用

Also Published As

Publication number Publication date
CN116744978A (zh) 2023-09-12
US20240091370A1 (en) 2024-03-21
CA3200056A1 (en) 2022-06-16
WO2022125904A1 (en) 2022-06-16
EP4259212A1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
EP4048315B1 (en) Thienoazepine immunoconjugates, and uses thereof
JP2022549510A (ja) アミド結合したアミノベンズアゼピン免疫複合体、及びその使用
TWI906429B (zh) 抗ｃｅａ免疫結合物及其用途
WO2021046112A1 (en) Aminoquinoline compounds, immunoconjugates, and uses thereof
JP2023552792A (ja) 抗ｈｅｒ２免疫複合体、及びその使用
JP2024511088A (ja) ２－アミノ－４－カルボキサミド－ベンゾアゼピン免疫複合体、及びその使用
WO2023154318A1 (en) Anti-tr0p2, aminobenzazepine immunoconjugates, and uses thereof
JP2023552791A (ja) 抗ｈｅｒ２免疫複合体、及びその使用
JP2024501453A (ja) 抗ｃｅａイムノコンジュゲート、及びそれらの使用
JP2023552790A (ja) 抗ｐｄ－ｌ１イムノコンジュゲート、及びそれらの使用
JP2024512056A (ja) ２－アミノ－４－カルボキサミド－ベンゾアゼピン免疫複合体、及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260113